Document Detail

Efficacy and safety of cholesterol-lowering treatment.
MedLine Citation:
PMID:  16473115     Owner:  NLM     Status:  MEDLINE    
Malcolm Law; Nicholas J Wald
Related Documents :
6197205 - Comparison of the du pont aca and dow methods for determination of high-density lipopro...
25410905 - Cholesteryl ester transfer protein (cetp)deficiency and cetp inhibitors.
2242345 - Side-chain cleavage of cholesterol sulfate by ovarian mitochondria.
2332425 - Conversion of cholesterol to pregnenolone mobilizes cytochrome p-450 in the inner membr...
16935845 - Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects...
6767525 - Power spectral analysis of the eeg following protein malnutrition.
Publication Detail:
Type:  Comment; Letter    
Journal Detail:
Title:  Lancet     Volume:  367     ISSN:  1474-547X     ISO Abbreviation:  Lancet     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-02-13     Completed Date:  2006-02-23     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  England    
Other Details:
Languages:  eng     Pagination:  469-70; author reply 470-1     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cholesterol, LDL / blood
Coronary Disease / prevention & control
Dose-Response Relationship, Drug
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  therapeutic use*
Hypercholesterolemia / drug therapy*
Time Factors
Reg. No./Substance:
0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors
Comment On:
Lancet. 2005 Oct 8;366(9493):1267-78   [PMID:  16214597 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Back pain emergencies.
Next Document:  Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct hum...